Coadministration of sertraline with cisapride or pimozide: an open-label, nonrandomized examination of pharmacokinetics and corrected QT intervals in healthy adult volunteers
- PMID:16154484
- DOI: 10.1016/j.clinthera.2005.07.013
Coadministration of sertraline with cisapride or pimozide: an open-label, nonrandomized examination of pharmacokinetics and corrected QT intervals in healthy adult volunteers
Abstract
Background: Sertraline hydrochloride is a selective serotonin reuptake inhibitor with demonstrated efficacy and safety for the treatment of the following disorders: major depressive, obsessive-compulsive, panic, premenstrual dysphoric, social anxiety, and posttraumatic stress. Although sertraline is unlikely to cause clinically significant inhibition of cytochrome P450 (CYP) 3A4 substrates, even modest concentration increases for narrow therapeutic index drugs, such as pimozide or cisapride, are potentially important.
Objective: The goal of this study was to determine whether there is a pharmacokinetic interaction, as shown by plasma concentrations and electrocardiographic evidence of QTc intervals, between sertraline 200 mg QD and cisapride 10 mg QID, and between sertraline 200 mg QD and pimozide (single 2-mg dose).
Methods: Patients in group A were administered cisapride on days 1 and 2 (10 mg QID), day 3 (10 mg/d), days 25 through 29 (10 mg QID), and day 30 (10 mg/d). Sertraline was administered on days 4 through 29 at a starting dose of 50 mg/d, which was titrated upward in 50-mg increments every third day to a maximum of 200 mg/d. Patients in group B were treated with 2 mg of pimozide on days 1 and 39. Sertraline was administered on days 18 through 46 at a starting dose of 50 mg/d, which was titrated upward in 50-mg increments every third day to a maximum of 200 mg/d.
Results: There were 9 males and 6 females in group A (sertraline + cisapride) (mean age, 34.4 years for males, 41.7 years for females; mean weight, 78.7 kg for males, 66.6 kg for females; 14 Hispanic, 1 white), and 8 males and 7 females in group B (sertraline + pimozide) (mean age, 26.1 years for males, 33.4 years for females; mean weight, 70.8 kg for males, 61.4 kg for females; 15 Hispanic). Coadministration of sertraline and cisapride resulted in statistically significant reductions of 29% and 36% in cisapride C(max) and AUC from time 0 to 6 hours, respectively, compared with cisapride alone. Coadministration of sertraline and pimozide resulted in statistically significant increases of 35% and 37% in pimozide Cmax and AUC(0-infinity), respectively, compared with pimozide alone. No subject exhibited a prolongation of the QTc interval > or =15% with coadministration of sertraline and cisapride, or sertraline and pimozide.
Conclusions: This study found that coadministration of sertraline with cisapride resulted in decreases in cisapride concentrations, and no significant effects on QTc intervals. Coadministration of sertraline 200 mg/d and a single dose of pimozide 2 mg produced significant increases in pimozide concentrations but no prolongation of the QTc interval > or =15%. This opposite effect for pimozide compared with cisapride, as well as other previously tested CYP3A4 substrates, suggests that there are mechanisms other than CYP3A4 involved in the sertraline-pimozide interaction.
Similar articles
- Drug interaction between mosapride and erythromycin without electrocardiographic changes.Katoh T, Saitoh H, Ohno N, Tateno M, Nakamura T, Dendo I, Kobayashi S, Nagasawa K.Katoh T, et al.Jpn Heart J. 2003 Mar;44(2):225-34. doi: 10.1536/jhj.44.225.Jpn Heart J. 2003.PMID:12718484
- Influence of coadministration of fluoxetine on cisapride pharmacokinetics and QTc intervals in healthy volunteers.Zhao Q, Wojcik MA, Parier JL, Pesco-Koplowitz L.Zhao Q, et al.Pharmacotherapy. 2001 Feb;21(2):149-57. doi: 10.1592/phco.21.2.149.34109.Pharmacotherapy. 2001.PMID:11213850Clinical Trial.
- The influence of cisapride and clarithromycin on QT intervals in healthy volunteers.van Haarst AD, van 't Klooster GA, van Gerven JM, Schoemaker RC, van Oene JC, Burggraaf J, Coene MC, Cohen AF.van Haarst AD, et al.Clin Pharmacol Ther. 1998 Nov;64(5):542-6. doi: 10.1016/S0009-9236(98)90137-0.Clin Pharmacol Ther. 1998.PMID:9834046Clinical Trial.
- Drug interactions with cisapride: clinical implications.Michalets EL, Williams CR.Michalets EL, et al.Clin Pharmacokinet. 2000 Jul;39(1):49-75. doi: 10.2165/00003088-200039010-00004.Clin Pharmacokinet. 2000.PMID:10926350Review.
- The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders.MacQueen G, Born L, Steiner M.MacQueen G, et al.CNS Drug Rev. 2001 Spring;7(1):1-24. doi: 10.1111/j.1527-3458.2001.tb00188.x.CNS Drug Rev. 2001.PMID:11420570Free PMC article.Review.
Cited by
- Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency.Yeung CK, Fujioka Y, Hachad H, Levy RH, Isoherranen N.Yeung CK, et al.Clin Pharmacol Ther. 2011 Jan;89(1):105-13. doi: 10.1038/clpt.2010.252. Epub 2010 Dec 1.Clin Pharmacol Ther. 2011.PMID:21124313Free PMC article.
- Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trials.Wiśniowska B, Tylutki Z, Wyszogrodzka G, Polak S.Wiśniowska B, et al.BMC Pharmacol Toxicol. 2016 Mar 10;17:12. doi: 10.1186/s40360-016-0053-1.BMC Pharmacol Toxicol. 2016.PMID:26960809Free PMC article.Review.
- Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data.Isoherranen N, Lutz JD, Chung SP, Hachad H, Levy RH, Ragueneau-Majlessi I.Isoherranen N, et al.Chem Res Toxicol. 2012 Nov 19;25(11):2285-300. doi: 10.1021/tx300192g. Epub 2012 Sep 27.Chem Res Toxicol. 2012.PMID:22823924Free PMC article.Review.
- The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PD.Davies SJ, Mulsant BH, Flint AJ, Meyers BS, Rothschild AJ, Whyte EM, Kirshner MM, Sorisio D, Pollock BG, Bies RR.Davies SJ, et al.Clin Pharmacokinet. 2015 Nov;54(11):1161-8. doi: 10.1007/s40262-015-0275-1.Clin Pharmacokinet. 2015.PMID:25971243Clinical Trial.
- The QT interval and psychotropic medications in children: recommendations for clinicians.McNally P, McNicholas F, Oslizlok P.McNally P, et al.Eur Child Adolesc Psychiatry. 2007 Feb;16(1):33-47. doi: 10.1007/s00787-006-0573-0. Epub 2006 Aug 29.Eur Child Adolesc Psychiatry. 2007.PMID:16944043Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources